Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01625611 · ClinicalTrials.gov registry record · Phase 1
Kappa-PET Imaging and Naltrexone in Alcohol Drinking Behaviors
A Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 1
- Development phase
- 59
- Enrollment target
NCT01625611 is a Phase 1 study that has completed, run by Yale University. The registered enrollment target is 59 participants.
The verdict
NCT01625611, a Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 59 participants
- Enrollment target
Study Summary
The primary purpose of the study is to increase our knowledge of receptor function in the brains of people who are heavy drinkers and taking naltrexone (NTX), a medication that has been approved for the treatment of alcohol dependence. Receptors are special molecules in the brain to which other molecules (neurotransmitters) attach during the normal every-day workings of the brain. Drugs can bind to those receptor molecules as well. Recent evidence suggests that kappa opioid receptors (KOR's) may play an important role in alcohol drinking behavior. This study will try to determine if naltrexone's ability to attach to these receptors is related to its effectiveness. We will use PET (positron emission tomography) for this study. PET is a type of imaging device found in nuclear medicine. It is used for tracking the presence of injected radioactive materials in the body.
Interventions
- DRUG Naltrexone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2011-02 |
| Est. Completion | 2021-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01625611
The ClinicalTrials.gov registry entry for NCT01625611 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Naltrexone is the first listed.
NCT01625611 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01625611 about?
NCT01625611 is a clinical study titled "Kappa-PET Imaging and Naltrexone in Alcohol Drinking Behaviors". The primary purpose of the study is to increase our knowledge of receptor function in the brains of people who are heavy drinkers and taking naltrexone (NTX), a medication that has been approved for the treatment of alcohol dependence. Receptors are special molecules in the brain to which other mole...
What is the current status of trial NCT01625611?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 59 participants. The study started on 2011-02. Estimated completion is 2021-06-30.
What interventions are being tested in trial NCT01625611?
The interventions under investigation include: Naltrexone (DRUG).
Who is sponsoring clinical trial NCT01625611?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.